Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

Myriad Genetics (MYGN)

Myriad Genetics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MYGN
DateTimeSourceHeadlineSymbolCompany
06/02/202513:30GlobeNewswire Inc.Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer TestNASDAQ:MYGNMyriad Genetics Inc
05/02/202521:15GlobeNewswire Inc.Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) AssayNASDAQ:MYGNMyriad Genetics Inc
05/02/202513:30GlobeNewswire Inc.Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink IntegrationNASDAQ:MYGNMyriad Genetics Inc
30/01/202521:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MYGNMyriad Genetics Inc
29/01/202513:30GlobeNewswire Inc.Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine ConferenceNASDAQ:MYGNMyriad Genetics Inc
23/01/202513:30GlobeNewswire Inc.Myriad Genetics Introduces Online Prenatal Genetic Testing ResourceNASDAQ:MYGNMyriad Genetics Inc
21/01/202513:30GlobeNewswire Inc.Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & GynecologyNASDAQ:MYGNMyriad Genetics Inc
15/01/202513:39Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MYGNMyriad Genetics Inc
15/01/202513:30GlobeNewswire Inc.Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial GuidanceNASDAQ:MYGNMyriad Genetics Inc
09/01/202521:30GlobeNewswire Inc.Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer HistoryNASDAQ:MYGNMyriad Genetics Inc
08/01/202516:27GlobeNewswire Inc.UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:MYGNMyriad Genetics Inc
08/01/202513:00GlobeNewswire Inc.Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:MYGNMyriad Genetics Inc
07/01/202513:00GlobeNewswire Inc.MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assayNASDAQ:MYGNMyriad Genetics Inc
06/01/202513:00GlobeNewswire Inc.Myriad Genetics Issues Quality, Innovation, and Corporate Responsibility ReportNASDAQ:MYGNMyriad Genetics Inc
02/01/202521:26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MYGNMyriad Genetics Inc
19/12/202421:15GlobeNewswire Inc.Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human GeneticsNASDAQ:MYGNMyriad Genetics Inc
12/12/202421:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MYGNMyriad Genetics Inc
11/12/202421:36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MYGNMyriad Genetics Inc
11/12/202421:36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MYGNMyriad Genetics Inc
10/12/202423:26GlobeNewswire Inc.Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic TestingNASDAQ:MYGNMyriad Genetics Inc
10/12/202421:51Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MYGNMyriad Genetics Inc
10/12/202421:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MYGNMyriad Genetics Inc
10/12/202421:05GlobeNewswire Inc.Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board MemberNASDAQ:MYGNMyriad Genetics Inc
09/12/202421:05GlobeNewswire Inc.Myriad Genetics to Present New Data at San Antonio Breast Cancer SymposiumNASDAQ:MYGNMyriad Genetics Inc
09/12/202413:00GlobeNewswire Inc.NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic AssessmentNASDAQ:MYGNMyriad Genetics Inc
02/12/202421:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MYGNMyriad Genetics Inc
26/11/202421:42Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MYGNMyriad Genetics Inc
20/11/202421:30GlobeNewswire Inc.Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2NASDAQ:MYGNMyriad Genetics Inc
19/11/202413:00GlobeNewswire Inc.Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into PregnancyNASDAQ:MYGNMyriad Genetics Inc
14/11/202421:16Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:MYGNMyriad Genetics Inc
 Showing the most relevant articles for your search:NASDAQ:MYGN